Log in
NASDAQ:NEO

NeoGenomics Stock Forecast, Price & News

$47.26
+0.16 (+0.34 %)
(As of 12/2/2020 12:00 AM ET)
Add
Compare
Today's Range
$46.25
Now: $47.26
$47.55
50-Day Range
$38.22
MA: $42.71
$47.58
52-Week Range
$20.47
Now: $47.26
$47.94
Volume477,367 shs
Average Volume873,767 shs
Market Capitalization$5.25 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.68
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, as well as laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services, which focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides morphologic analysis which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics, Inc. has a strategic collaboration with Inivata Limited for the commercialization of its InVisionFirst-Lung liquid biopsy test in the United States. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
NeoGenomics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.6Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.57 out of 5 stars


Industry, Sector and Symbol

Industry Testing laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NEO
CUSIPN/A
Phone239-768-0600
Employees1,700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$408.83 million
Cash Flow$0.54 per share
Book Value$6.00 per share

Profitability

Net Income$8.01 million

Miscellaneous

Market Cap$5.25 billion
Next Earnings Date2/25/2021 (Estimated)
OptionableOptionable
$47.26
+0.16 (+0.34 %)
(As of 12/2/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NEO News and Ratings via Email

Sign-up to receive the latest news and ratings for NEO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











NeoGenomics (NASDAQ:NEO) Frequently Asked Questions

How has NeoGenomics' stock price been impacted by COVID-19 (Coronavirus)?

NeoGenomics' stock was trading at $24.78 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NEO shares have increased by 90.7% and is now trading at $47.2550.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of NeoGenomics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 9 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for NeoGenomics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than NeoGenomics?

Wall Street analysts have given NeoGenomics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but NeoGenomics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is NeoGenomics' next earnings date?

NeoGenomics is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for NeoGenomics
.

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) announced its earnings results on Tuesday, October, 27th. The medical research company reported $0.06 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.04 by $0.02. The medical research company had revenue of $125.40 million for the quarter, compared to analysts' expectations of $126.23 million. NeoGenomics had a negative net margin of 1.16% and a positive return on equity of 0.71%. NeoGenomics's revenue was up 19.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.07 earnings per share.
View NeoGenomics' earnings history
.

What price target have analysts set for NEO?

10 equities research analysts have issued twelve-month price objectives for NeoGenomics' stock. Their forecasts range from $14.50 to $50.00. On average, they anticipate NeoGenomics' share price to reach $40.95 in the next twelve months. This suggests that the stock has a possible downside of 13.3%.
View analysts' price targets for NeoGenomics
.

Who are some of NeoGenomics' key competitors?

What other stocks do shareholders of NeoGenomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology Group (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Square (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).

Who are NeoGenomics' key executives?

NeoGenomics' management team includes the following people:
  • Mr. Douglas M. VanOort, Chairman & CEO (Age 65, Pay $1.57M)
  • Ms. Kathryn B. McKenzie, Chief Financial Officer (Age 36, Pay $400k)
  • Mr. George A. Cardoza, Pres of Pharma Services Division (Age 58, Pay $645k)
  • Mr. Robert J. Shovlin, Pres of Clinical Services Division (Age 49, Pay $683k)
  • Dr. Lawrence M. Weiss M.D., Chief Medical Officer & Chairman of Scientific Advisory Board (Age 64, Pay $860k)
  • Mr. Steven A. Ross, VP & Chief Information Officer (Age 56)
  • Charlie Eidson, Mang. of Investor Relations and Strategy & Corp. Devel.
  • Ms. Denise E. Pedulla, Gen. Counsel & Corp. Sec. (Age 60)
  • Ms. Stephanie K. Bywater, Chief Compliance Officer (Age 49)
  • Mr. Douglas M. Brown, Chief Strategy & Corp. Devel. Officer (Age 50)

What is NeoGenomics' stock symbol?

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

Who are NeoGenomics' major shareholders?

NeoGenomics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.76%), State Street Corp (2.83%), Emerald Advisers LLC (1.24%), Federated Hermes Inc. (0.92%), Granite Investment Partners LLC (0.89%) and New York State Common Retirement Fund (0.88%). Company insiders that own NeoGenomics stock include Bruce K Crowther, Electric Co General, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven C Jones and William Bonello.
View institutional ownership trends for NeoGenomics
.

Which major investors are selling NeoGenomics stock?

NEO stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., BlackRock Inc., Arrowstreet Capital Limited Partnership, Great West Life Assurance Co. Can, Castleark Management LLC, Norris Perne & French LLP MI, State Street Corp, and Emerald Advisers LLC. Company insiders that have sold NeoGenomics company stock in the last year include Bruce K Crowther, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Oort Douglas M Van, Robert J Shovlin, Steven C Jones, and William Bonello.
View insider buying and selling activity for NeoGenomics
.

Which major investors are buying NeoGenomics stock?

NEO stock was acquired by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc., Cubist Systematic Strategies LLC, Voloridge Investment Management LLC, Wells Fargo & Company MN, CIBC Private Wealth Group LLC, Scout Investments Inc., Assenagon Asset Management S.A., and Skandinaviska Enskilda Banken AB publ.
View insider buying and selling activity for NeoGenomics
.

How do I buy shares of NeoGenomics?

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NeoGenomics' stock price today?

One share of NEO stock can currently be purchased for approximately $47.26.

How big of a company is NeoGenomics?

NeoGenomics has a market capitalization of $5.25 billion and generates $408.83 million in revenue each year. The medical research company earns $8.01 million in net income (profit) each year or $0.23 on an earnings per share basis. NeoGenomics employs 1,700 workers across the globe.

What is NeoGenomics' official website?

The official website for NeoGenomics is www.neogenomics.com.

How can I contact NeoGenomics?

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected]

This page was last updated on 12/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.